The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK
Open Access
- 1 October 2015
- journal article
- research article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 10 (1) , 2207-2217
Abstract
Background: Real-world prescription pathways leading to triple therapy (TT) (inhaled corticosteroid [ICS] plus long-acting β2-agonist bronchodilator [LABA] plus long-acting muscarinic antagonist) differ from Global initiative for chronic Obstructive Lung Disease [GOLD] and National Institute for Health and Care Excellence treatment recommendations. This study sets out to identify COPD patients without asthma receiving TT, and determine the pathways taken from diagnosis to the first prescription of TT. Methods: This was a historical analysis of COPD patients without asthma from the Optimum Patient Care Research Database (387 primary-care practices across the UK) from 2002 to 2010. Patient disease severity was classified using GOLD 2013 criteria. Data were analyzed to determine prescribing of TT before, at, and after COPD diagnosis; the average time taken to receive TT; and the impact of lung function grade, modified Medical Research Council dyspnea score, and exacerbation history on the pathway to TT. Results: During the study period, 32% of patients received TT. Of these, 19%, 28%, 37%, and 46% of patients classified as GOLD A, B, C, and D, respectively, progressed to TT after diagnosis (PP=0.065). The most common prescription pathway to TT was LABA plus ICS. It was observed that exacerbation history did influence the pathway of LABA plus ICS to TT. Conclusion: Real life UK prescription data demonstrates the inappropriate prescribing of TT and confirms that starting patients on ICS plus LABA results in the inevitable drift to overuse of TT. This study highlights the need for dissemination and implementation of COPD guidelines to physicians, ensuring that patients receive the recommended therapy.Keywords
This publication has 44 references indexed in Scilit:
- Targeted therapy with inhaled corticosteroids in COPD according to blood eosinophil countsThe Lancet Respiratory Medicine, 2015
- Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPDNew England Journal of Medicine, 2014
- Why doesn't reducing exacerbations decrease COPD mortality?The Lancet Respiratory Medicine, 2014
- Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)Respiratory Research, 2014
- Overtreatment of COPD with Inhaled Corticosteroids - Implications for Safety and Costs: Cross-Sectional Observational StudyPLOS ONE, 2013
- Everyday clinical practice and its relationship to 2010 and 2011 GOLD guideline recommendations for the management of COPDPrimary Care Respiratory Journal, 2013
- Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroidsInternational Journal of Chronic Obstructive Pulmonary Disease, 2012
- The effect of adding inhaled corticosteroids to tiotropium and long-acting beta 2 -agonists for chronic obstructive pulmonary diseaseCochrane Database of Systematic Reviews, 2011
- Steroids in COPD: still up in the air?: Fig. 1—European Respiratory Journal, 2010
- Effectiveness of Fluticasone Propionate and Salmeterol Combination Delivered via the Diskus Device in the Treatment of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2002